AnaptysBio (NASDAQ:ANAB) Releases Earnings Results, Misses Estimates By $0.82 EPS

AnaptysBio (NASDAQ:ANAB) posted its earnings results on Monday. The biotechnology company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82), Yahoo Finance reports. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. The firm had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.85 million.

AnaptysBio Price Performance

NASDAQ ANAB opened at $32.08 on Wednesday. The company has a market cap of $876.39 million, a PE ratio of -5.22 and a beta of -0.25. The stock’s 50 day simple moving average is $27.86 and its 200-day simple moving average is $25.05. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $38.85.

Wall Street Analyst Weigh In

ANAB has been the subject of several analyst reports. JPMorgan Chase & Co. upgraded AnaptysBio from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $29.00 to $69.00 in a report on Friday, July 19th. Wells Fargo & Company initiated coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of AnaptysBio in a report on Tuesday. SVB Leerink started coverage on shares of AnaptysBio in a research report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $34.00 price objective on shares of AnaptysBio in a research report on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.89.

Insider Transactions at AnaptysBio

In related news, Director Dennis M. Fenton sold 1,950 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $23.17, for a total transaction of $45,181.50. Following the completion of the sale, the director now owns 1,950 shares of the company’s stock, valued at approximately $45,181.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. Following the transaction, the insider now directly owns 11,618 shares of the company’s stock, valued at $406,630. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dennis M. Fenton sold 1,950 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $23.17, for a total transaction of $45,181.50. Following the completion of the transaction, the director now owns 1,950 shares in the company, valued at $45,181.50. The disclosure for this sale can be found here. Insiders have sold 16,900 shares of company stock valued at $484,824 over the last ninety days. Insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.